Clinical Trials · NCT03891875
ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Stealth BioTherapeutics Inc.
- Enrollment
- 176
- Start date
- Mar 2019
- Locations
- 37 sites, United States
- Primary endpoint
- LL BCVA Score Change From Baseline